Press Releases in 2017

Surge in RNAscope and BaseScope Assay publications now includes pharma, biotech and new research areas - and use as a core assay

Minneapolis, MN - November 20, 2017 - Bio-Techne updated its Flow Cytometry Panel Builder tool in July 2017 to support the use of its vast selection of over 18,000 conjugated antibodies, across targets and colors. The Flow Cytometry Panel Builder, a version of the FluoroFinder tool, was first launched in 2014 when this tool first became available to the scientific community. FluoroFinder® is a software company (a Software as a Service or SaaS) that specializes in experimental design and reagent search tools for flow cytometry and more recently, microscopy.

Bio-Techne Awards 40,000 USD Research Grant to Innovative Cancer Researcher

Melbourne-based melanoma researcher selected as the winner of ‘RNAscope ISH Get Hybridized’ giveaway, supporting cutting-edge research

LONDON, Oct. 5, 2017 /PRNewswire/ -- Bio-Techne has been selected as a supplier of research antibodies under Lot 1: Antibodies of the Southern Universities Purchasing Consortium (SUPC), Antibodies and Sera Framework Agreement for the United Kingdom (UK) Higher Education Sector.

SAN JOSE, Calif., Sept. 20, 2017 /PRNewswire/ -- ProteinSimple®, a Bio-Techne brand, announced today an expansion of the Ella immunoassay platform with the launch of a 32x4 Simple Plex™ cartridge. This new cartridge simultaneously measures up to 32 different samples from serum, plasma, cell culture supernatants and other bodily fluids against four different analytes of interest. Doubling the current sample throughput while maintaining a total immunoassay time of 85 minutes, this new cartridge enables greater efficiency at a lower cost per reportable result.

MINNEAPOLIS, Sept. 6, 2017 /PRNewswire/ -- R&D Systems®, a Bio-Techne brand, announced today the release of a new rapid, solid phase, enzyme-linked immunosorbent assay (ELISA) designed to measure anti-Zika virus immunoglobulin G (IgG) antibodies in human serum. A unique feature of this assay is that, prior to performing the test, samples are pre-treated with a proprietary reagent designed to minimize any interfering proteins present in the serum which could produce a false positive result.